Content area
Full Text
In a single centre, retrospective study of 14 patients, one man and woman [ages not stated] were described, who developed grade 2 stomatitis and grade 2 dysgeusia during treatment with afatinib [routes and dosages not stated; not all outcomes stated].
Patient 1: The man had non-small cell lung cancer and was treated with afatinib. Within two weeks of...